<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(5)</volume><submitter>Zhang L</submitter><pubmed_abstract>Phosphorylation of tau at Ser (396, 404) (p-tau&lt;sup>396,404&lt;/sup>) is one of the earliest phosphorylation events, and plasma p-tau&lt;sup>396,404&lt;/sup> level appears to be a potentially promising biomarker of Alzheimer's disease (AD). The low abundance and easy degradation of p-tau in the plasma make the lateral flow assay (LFA) a suitable choice for point-of-care detection of plasma p-tau&lt;sup>396,404&lt;/sup> levels. Herein, based on our screening of a pair of p-tau&lt;sup>396,404&lt;/sup>-specific antibodies, we developed a colorimetric and surface-enhanced Raman scattering (SERS) dual-readout LFA for the rapid, highly sensitive, and robust detection of plasma p-tau&lt;sup>396,404&lt;/sup> levels. This LFA realized a detection limit of 60 pg/mL by the naked eye or 3.8 pg/mL by SERS without cross-reacting with other tau species. More importantly, LFA rapidly and accurately differentiated AD patients from healthy controls, suggesting that it has the potential for clinical point-of-care application in AD diagnosis. This dual-readout LFA has the advantages of simple operation, rapid, and ultra-sensitive detection, providing a new way for early AD diagnosis and intervention, especially in primary and community AD screening.&lt;h4>Electronic supplementary material&lt;/h4>Supplementary material (characterization of AuNPs and 4-MBA@AuNP probe; the optimal 4-MBA load for AuNPs; the optimal K2CO3 volumes for 4-MBA@AuNP-3G5 conjugates; the optimal 3G5 load for 4-MBA@AuNP conjugates; effect of NaCl concentration on 4-MBA@AuNP-3G5 stability; the linear curve of T-line color and SERS intensity versus different p-tau396,404 concentrations; the comparison of colorimetric-based LFA test results and the diagnosis results; Raman intensities and antibody activity of 4-MBA@AuNP-3G5 before and after storage; colorimetric intensity of dual-readout LFA detecting different concentrations of p-tau396,404 protein; sequence of synthesized peptides used in this study; information of the participants in this study; the information of antibodies used in this study) is available in the online version of this article at 10.1007/s12274-022-5354-4.</pubmed_abstract><journal>Nano research</journal><pagination>7459-7469</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9971675</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay.</pubmed_title><pmcid>PMC9971675</pmcid><pubmed_authors>Cao K</pubmed_authors><pubmed_authors>Luo Q</pubmed_authors><pubmed_authors>Liang X</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Luo H</pubmed_authors><pubmed_authors>Su Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay.</name><description>Phosphorylation of tau at Ser (396, 404) (p-tau&lt;sup>396,404&lt;/sup>) is one of the earliest phosphorylation events, and plasma p-tau&lt;sup>396,404&lt;/sup> level appears to be a potentially promising biomarker of Alzheimer's disease (AD). The low abundance and easy degradation of p-tau in the plasma make the lateral flow assay (LFA) a suitable choice for point-of-care detection of plasma p-tau&lt;sup>396,404&lt;/sup> levels. Herein, based on our screening of a pair of p-tau&lt;sup>396,404&lt;/sup>-specific antibodies, we developed a colorimetric and surface-enhanced Raman scattering (SERS) dual-readout LFA for the rapid, highly sensitive, and robust detection of plasma p-tau&lt;sup>396,404&lt;/sup> levels. This LFA realized a detection limit of 60 pg/mL by the naked eye or 3.8 pg/mL by SERS without cross-reacting with other tau species. More importantly, LFA rapidly and accurately differentiated AD patients from healthy controls, suggesting that it has the potential for clinical point-of-care application in AD diagnosis. This dual-readout LFA has the advantages of simple operation, rapid, and ultra-sensitive detection, providing a new way for early AD diagnosis and intervention, especially in primary and community AD screening.&lt;h4>Electronic supplementary material&lt;/h4>Supplementary material (characterization of AuNPs and 4-MBA@AuNP probe; the optimal 4-MBA load for AuNPs; the optimal K2CO3 volumes for 4-MBA@AuNP-3G5 conjugates; the optimal 3G5 load for 4-MBA@AuNP conjugates; effect of NaCl concentration on 4-MBA@AuNP-3G5 stability; the linear curve of T-line color and SERS intensity versus different p-tau396,404 concentrations; the comparison of colorimetric-based LFA test results and the diagnosis results; Raman intensities and antibody activity of 4-MBA@AuNP-3G5 before and after storage; colorimetric intensity of dual-readout LFA detecting different concentrations of p-tau396,404 protein; sequence of synthesized peptides used in this study; information of the participants in this study; the information of antibodies used in this study) is available in the online version of this article at 10.1007/s12274-022-5354-4.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2024-11-20T06:41:55.777Z</modification><creation>2024-11-20T06:41:55.777Z</creation></dates><accession>S-EPMC9971675</accession><cross_references><pubmed>37223429</pubmed><doi>10.1007/s12274-022-5354-4</doi></cross_references></HashMap>